Home
cogent | precision therapies for gene...

cogent | precision thera... Market Share Analysis for June 2026

cogent biosciences is rationally designing precision therapies that treat the underlying cause of disease to improve patients’ lives.

Health > Biotechnology and Pharmaceuticals

Domainunumrx.com

Year Founded--

Employees51 - 200

Annual Revenue--

cogent | precision therapies for gene...

cogent | precision therapies for gene... (including company regionals)

unumrx.com

See more website traffic and engagement information

Total visits to cogent | precision therapies for gene...'s top domains

Understand cogent | precision therapies for gene... market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in cogent | precision therapies for gene...'s top domains

Analyze cogent | precision therapies for gene... engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on cogent | precision therapies for gene...'s top domains

See how cogent | precision therapies for gene... keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

cogent | precision therapies for gene... top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by cogent | precision therapies for gene...

These are the website technologies, by industry, used by cogent | precision therapies for gene... top domains

Audio Video Media (2)

Vimeo

Content Management System (2)

WordPress

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

More Technologies

6

See all

News & Signals from cogent | precision therapies for gene...

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsUnumrx is developing novel antibody-coupled T-cell receptor therapies for cancer on Jan 1st '15.Seattle Genetics, Inc. and Unum Therapeutics, Inc. in 2015 entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer.

NewsUnumrx hires Peter Harwin as board chair.In other company news, Unum has appointed Peter Harwin as its board chair.

NewsSeattle Genetics partnered with Unumrx on Jan 1st '15.Impact of the COVID-19 on Anti-body Coupled T Receptor Therapy Market to See Huge Growth by 2027 | Seattle Genetics, Inc. and Unum Therapeutics, Inc The report offers a systematic presentation of the existing trends, growth opportunities, market dynamics that are expected to shape the growth of the Anti-body Coupled T Receptor Therapy market.